Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Table 1
Characteristics of the included studies.
Author
Year
Journal
Drug
Time to evaluate
Primary endpoint
Group
Total
Male, (%)
Age (mean age)
Duration of psoriasis (years)
Involved body surface area (%)
Baseline PASI score
Papp (AMAGINE-1)
2016
BJD
Brodalumab
12
PASI 75
210 mg
222
161 (73)
sPGA 0/1
140 mg
219
162 (74)
Placebo
220
161 (73)
Lebwohl (AMAGINE-2)
2015
NEJM
Brodalumab
12
PASI 75
210 mg
612
421 (69)
sPGA 0/1
140 mg
610
413 (68)
PASI 100
Ustekinumab
300
205 (68)
Placebo
309
219 (71)
Lebwohl (AMAGINE-3)
2015
NEJM
Brodalumab
12
PASI 75
210 mg
624
431 (69)
sPGA 0/1
140 mg
629
437 (70)
PASI 100
Ustekinumab
313
212 (68)
Placebo
315
208 (66)
Papp
2012
NEJM
Brodalumab
12
PASI 75
210 mg
39
28 (72)
PASI 100
140 mg
39
22 (56)
Placebo
42
30 (71)
Nakagawa
2015
JDS
Brodalumab
12
PASI 75
210 mg
37
29 (78.4)
PASI 100
140 mg
37
30 (81.1)
sPGA 0/1
Placebo
38
27 (71.1)
Rich
2012
BJD
Secukinumab
12
PASI 75
150 mg
133
105 (78.9)
Placebo
67
44 (65.7)
Paul (JUNCTURE)
2015
JEADV
Secukinumab
12
PASI 75
300 mg
60
46 (76.7)
IGA 0/1
150 mg
61
41 (67.2)
Placebo
61
38 (62.3)
Langley (ERASURE)
2014
NEJM
Secukinumab
12
PASI 75
300 mg
245
169 (69.0)
IGA 0/1
150 mg
245
168 (68.6)
Placebo
248
172 (69.4)
Langley (FIXTURE)
2014
NEJM
Secukinumab
12
PASI 75
300 mg
327
224 (68.5)
IGA 0/1
150 mg
327
236 (72.2)
Placebo
326
237 (72.7)
Blauvelt (FEATURE)
2015
BJD
Secukinumab
12
PASI 75
300 mg
59
38 (64.4)
IGA 0/1
150 mg
59
40 (67.8)
Placebo
59
39 (66.1)
Gordon (UNCOVER-1)
2016
NEJM
Ixekizumab
12
PASI 75
80 mg Q4W
432
289 (66.9)
sPGA 0/1
80 mg Q2W
433
291 (67.2)
Placebo
431
303 (70.3)
Griffiths (UNCOVER-2)
2015
Lancet
Ixekizumab
12
PASI 75
80 mg Q4W
347
244 (70.3)
sPGA 0/1
80 mg Q2W
351
221 (63.0)
Placebo
168
120 (71.4)
Griffiths (UNCOVER-3)
2015
Lancet
Ixekizumab
12
PASI 75
80 mg Q4W
386
258 (66.8)
sPGA 0/1
80 mg Q2W
385
254 (66.0)
Placebo
193
137 (71.0)
IGARASHI
2012
JD
Ustekinumab
12
PASI 75
45 mg
64
53 (82.8)
45
90 mg
62
47 (75.8)
44
Placebo
32
26 (83.9)
49
Leonardi (PHOENIX 1)
2008
Lancet
Ustekinumab
12
PASI 75
45 mg
255
175 (68·6)
44.8
19.7
27.2
20.5
90 mg
256
173 (67·6)
46.2
19.6
25.2
19.7
Placebo
255
183 (71·8)
44.8
20.4
27.7
20.4
Papp (PHOENIX 2)
2008
Lancet
Ustekinumab
12
PASI 75
45 mg
409
283 (69·2)
45.1
19.3
25.9
19.4
90 mg
411
274 (66·7)
46.6
20.3
27.1
20.1
Placebo
410
283 (69·0)
47.0
20.8
26.1
19.4
Tsai (PEARL)
2011
JDS
Ustekinumab
12
PASI 75
45 mg
61
50 (82.0)
Placebo
60
53 (88.3)
Zhu (LOTUS)
2013
JDD
Ustekinumab
12
PASI 75
45 mg
160
125 (78.1)
Placebo
162
123 (75.9)
Krueger
2007
NEJM
Ustekinumab
12
PASI 75
45 mg
64
39 (61)
90 mg
64
52 (81)
Placebo
64
46 (72)
Blauvelt (VOYAGE 1)
2017
JAAD
Guselkumab
16
IGA 0/1
100 mg
329
240 (72.9)
PASI 90
Placebo
174
119 (68.4)
Reich (VOYAGE 2)
2017
JAAD
Guselkumab
16
IGA 0/1
100 mg
496
349 (70.4)
PASI 90
Placebo
248
173 (69.8)
Gordon
2015
NEJM
Guselkumab
16
PGA 0/1
50 mg
42
28 (67)
43
19
25
19
100 mg
42
31 (74)
42
18
24
21
Placebo
42
28 (67)
46.5
18
28
22
OHTSUKI
2017
JD
Guselkumab
16
IGA 0/1
50 mg
65
44 (67.7)
50.1
15.25
38.0
25.60
PASI 90
100 mg
63
47 (74.6)
47.8
14.39
37.9
26.73
Placebo
64
54 (84.4)
48.3
13.66
33.6
25.92
Papp
2015
BJD
Tildrakizumab
16
PASI 75
100 mg
89
76 (85)
NR
NR
NR
200 mg
86
65 (76)
NR
NR
NR
Placebo
46
38 (83)
NR
NR
NR
Reich (reSURFACE 1)
2017
Lancet
Tildrakizumab
12
PASI 75
100 mg
309
207 (67)
46.4
NR
29.7
20.0
PGA 0/1
200 mg
308
226 (73)
46.9
NR
30.9
20.7
Placebo
155
100 (65)
47.9
NR
29.6
19.3
Reich (reSURFACE 2)
2017
Lancet
Tildrakizumab
12
PASI 75
100 mg
307
220 (72)
44.6
NR
34.2
20.5
PGA 0/1
200 mg
314
225 (72)
44.6
NR
31.8
19.8
Placebo
313
222 (71)
45.8
NR
31.6
20.2
Gordon (UltIMMa-1)
2018
Lancet
Risankizumab
16
PASI 90
150 mg
304
212 (70)
48.3
NR
26.2
20.6
sPGA 0/1
Ustekinumab
100
70 (70)
46.5
NR
25.2
20.1
Placebo
102
79 (77)
49.3
NR
27.9
20.5
Gordon (UltIMMa-1)
2018
Lancet
Risankizumab
16
PASI 90
150 mg
294
203 (69)
46.2
NR
26.2
20.5
sPGA 0/1
Ustekinumab
99
66 (67)
48.6
NR
20.9
18.2
Placebo
98
67 (68)
46.3
NR
23.9
18.9
Data are presented as the numbers (%) or the . PASI 75: the percentages of patients with a 75% improvement from baseline in the PASI score; PASI 90: the percentages of patients with a 90% improvement from baseline in the PASI score; PASI 100: the percentages of patients with a 100% improvement from baseline in the PASI score; sPGA 0/1: static physician’s global assessment score of 0 or 1; IGA 0/1: a response of 0 or 1 on the modified investigator’s global assessment; PGA 0/1: physician’s global assessment score of 0 or 1; Q2W: every 2 weeks; Q4W: every 4 weeks; NR: not reported.